A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Capecitabine; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms DB-06; DESTINY-Breast06
- Sponsors AstraZeneca; AstraZeneca AB
- 04 Jun 2024 Results (As of Mar 18, 2024, n=866 ) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2024 Results presented in an AstraZeneca Media Release.
- 02 Jun 2024 Results presented in a Daiichi Sankyo Media Release.